Our manufacturing facility in Singapore is a key site for the MSD network and produces four of MSD’s top five products globally.

MSD Manufacturing Division, located in Tuas, first began operations in 1997.

Singapore has become a key strategic site in the MSD global manufacturing network, which consists of 43 manufacturing sites in 19 different countries, serving over 181 countries (as of Mar 2022).

As a leading biomedical sciences hub at the heart of the Asia Pacific region, Singapore is a location of choice to manufacture and package pharmaceutical products and vaccines in order to meet Asia Pacific healthcare needs. In 2001, the Asia Pacific Supply Chain Hub was established to manage supply and demand for the Asia Pacific region, including China and Japan.

The Singapore manufacturing site at Tuas is a multi-product facility that manufactures active pharmaceutical ingredients (APIs), oral solid dosage drug products (tablets), and will soon produce new generation inhaler medicines, as well as sterile filled vials and syringes and is home to new secondary packaging lines for cold-chain vaccines and biologics.

The site deploys a wide array of manufacturing technologies to support the production of medicines including some of MSD’s products for cancer, diabetes, and HIV.


The MSD Manufacturing Division is committed to be a world-class supplier, providing patients and customers with high-quality products and a reliable supply of safe and effective medicines and vaccines.